Atrium Therapeutics Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Atrium Therapeutics (Nasdaq: RNA) reported first quarter 2026 results and outlined key pipeline and corporate milestones following its February 27 spin-off and Nasdaq listing.
Q1 collaboration revenue was $19.6M, R&D expenses $16.7M, G&A expenses $20.3M, and cash stood at $267.8M, viewed as sufficient through proof-of-concept milestones.
Atrium earned a $15M milestone from Bristol Myers Squibb, advanced ATR 1072 toward an IND in 2H 2026, and plans an IND for ATR 1086 in 2027.
AI-generated analysis. Not financial advice.
Positive
- Q1 2026 collaboration revenue of $19.6M, including a $15M BMS milestone
- Cash and cash equivalents of $267.8M as of March 31, 2026
- Eligibility for up to $2.175B in potential BMS milestones plus tiered royalties
- Completion of GLP tox studies and pre-IND/CTA meetings for ATR 1072
- Planned ATR 1072 IND submission in 2H 2026 and Phase 1/2 trial start, pending clearance
- Planned ATR 1086 IND-enabling studies in 2026 and IND filing in 2027
Negative
- Q1 2026 R&D expenses of $16.7M for development and platform activities
- Q1 2026 G&A expenses of $20.3M, including public company launch costs
Key Figures
Market Reality Check
Peers on Argus
RNA was up 1.22% while key biotech peers like CRSP (-4.63%), MRUS (-7.08%), TGTX (-3.91%), PTCT (-1.57%) and NUVL (-1.2%) traded lower, pointing to stock-specific dynamics around this update.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | Earnings and merger | Positive | +1.2% | Q3 2025 results plus $12B Novartis merger and strong cash balance. |
| Aug 07 | Earnings update | Positive | -2.6% | Q2 2025 results with strong cash, rising R&D and multiple BLAs planned. |
| May 08 | Earnings and data | Positive | -2.9% | Q1 2025 results with positive del-zota topline data and solid cash. |
| Feb 27 | Earnings and pipeline | Positive | +5.4% | Q4 2024 results, strong $1.5B cash and multiple 2025 milestones. |
| Nov 07 | Earnings and trials | Positive | -1.7% | Q3 2024 results with advancing trials and higher R&D and G&A spend. |
Earnings and major strategic updates have produced mixed reactions, with more events showing negative than positive next-day moves despite generally constructive fundamentals.
Across prior earnings reports for Avidity (the predecessor to Atrium’s cardiology spin-out), updates often combined strong cash positions (up to $1.9 billion) and late-stage neuromuscular data with increased R&D and G&A spend. These events yielded modest average moves of about -0.1%, with several selloffs after fundamentally positive news. Today’s Atrium release continues the pattern of emphasizing balance sheet strength, collaboration milestones and clinical progress, now focused on precision cardiology programs ATR 1072 and ATR 1086.
Historical Comparison
Past RNA-tagged earnings events averaged a modest -0.1% move, often seeing pressure despite positive cash and pipeline updates. Today’s first Atrium-specific quarterly release fits into that pattern of news-heavy but valuation-sensitive reactions.
Earnings history shows a transition from Avidity’s late-stage neuromuscular portfolio, backed by up to $1.9 billion in cash and an eventual $12 billion Novartis deal, toward Atrium’s early-stage precision cardiology SpinCo, now reporting its own cash runway and collaboration-driven milestones.
Market Pulse Summary
This announcement highlights Atrium’s first full quarter as an independent public company, with collaboration revenue of $19.6 million, a $15 million BMS milestone and $267.8 million in cash supporting its precision cardiology pipeline. The update reiterates timelines for ATR 1072 and ATR 1086 and builds on a legacy of earnings events where strong cash positions and clinical progress coexisted with rising R&D and G&A expenses. Investors may watch execution on IND filings and early clinical data from ATR 1072 as key validation points.
Key Terms
good laboratory practice (glp) medical
investigational new drug (ind) regulatory
phase 1/2 clinical trial medical
cardiomyopathies medical
rna therapeutics technical
AI-generated analysis. Not financial advice.
"Our focused pipeline, strong cash balance and experienced team are driving significant momentum as we build a dedicated precision cardiology company," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "This quarter, we advanced our lead development programs, ATR 1072 and ATR 1086, while establishing the strategic and operational foundation required to pioneer RNA therapeutics in the precision cardiology space. With a clear strategy, a well-characterized RNA delivery platform and a deep commitment to patients, we believe we are well-positioned to advance therapies for people living with genetic cardiomyopathies who have limited or no therapeutic options."
Recent Highlights
- Launched as an independent, publicly traded precision cardiology company. Atrium launched on February 27, 2026 following its separation and spin-off from Avidity Biosciences, Inc. (Avidity) after Novartis AG's acquisition of Avidity. Atrium began trading on the Nasdaq Global Select Market under the ticker symbol "RNA."
- Earned
$15 million $15 million $1.35 billion in research and development milestone payments, up to approximately$825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. - Progressed ATR 1072 program toward the clinic. Atrium has conducted the Good Laboratory Practice (GLP) toxicology studies required for the submission of an Investigational New Drug (IND) application for ATR 1072, a potential treatment designed to address the underlying genetic cause of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. Additionally, the Company has completed initial discussions with both the
U.S. Food and Drug Administration (pre-IND meeting) and Health Canada (pre-CTA consultation meeting) regarding its proposed Phase 1/2 clinical trial design.
Anticipated Upcoming Milestones
- Submit IND application for ATR 1072 in the second half of 2026
- Initiate Phase 1/2 clinical trial for ATR 1072, subject to regulatory clearance
- File IND application for ATR 1086 in 2027, with IND-enabling studies initiating in 2026
First Quarter 2026 Financial Results
Given the timing of Atrium's spin-off from Avidity, the operating results presented for the first quarter of 2026 are not necessarily indicative of the results for any future periods.
- Collaboration Revenue: Collaboration revenue was
$19.6 million for the first quarter of 2026, primarily related to the achievement of a$15 million - Research and Development (R&D) Expenses: R&D expenses were
$16.7 million - General and Administrative (G&A) Expenses: G&A expenses were
$20.3 million - Cash and Cash Equivalents: As of March 31, 2026, Atrium had
$267.8 million
About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to the skeletal muscle and applies it for efficient delivery to the heart with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.
For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.
Availability of Other Information About Atrium Therapeutics
Investors and others should note that Atrium Therapeutics communicates with its investors and the public using its website https://atriumtherapeutics.com/, including, but not limited to, Atrium Therapeutics' disclosures, investor presentations and FAQs, Securities and Exchange Commission ("SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on LinkedIn. The information that Atrium Therapeutics posts on its website or on LinkedIn could be deemed to be material information. As a result, Atrium Therapeutics encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Atrium Therapeutics' website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
About PRKAG2 Syndrome
PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in heart muscle cells leading to thickened heart muscles, electrical conduction problems, and arrhythmias. There are 1,000 – 2,000 people with PRKAG2 syndrome in
About PLN Cardiomyopathy
Phospholamban ("PLN") cardiomyopathy is a rare autosomal dominant, progressive cardiac disease caused by mutations in PLN, a key regulator of sarcoplasmic reticulum Ca2+-ATPase 2a ("SERCA2a") calcium pump. PLN mutations produce protein aggregates that disrupt endoplasmic reticulum processes and lead to dilated, arrhythmogenic, or hypertrophic cardiomyopathies and a significantly increased risk of heart failure and sudden cardiac death. There are 2,000 – 4,000 people with pathogenic PLN variants in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding Atrium Therapeutics' ("Atrium's" or "our") future results of operations and financial condition; research and development plans; anticipated timing, design and conduct of ongoing and planned preclinical studies and clinical trials for product candidates; our expectations regarding our RNA delivery platform and ability to generate high-quality cardiology development candidates, the timing and likelihood of regulatory filings and approvals for product candidates; the potential safety and therapeutic benefits of our product candidates; the timing and likelihood of success; plans and objectives of management for future operations; and future results of anticipated product development efforts. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause Atrium's actual results to be materially different than those expressed in Atrium's forward-looking statements include but are not limited to: the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product candidates and the potential advantages of our product candidates compared to alternative therapies; the success and capabilities of the RNA delivery platform; the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market opportunity for our product candidates; the timing of and costs involved in obtaining and maintaining regulatory approval of our current and any future product candidates; our ability to develop our current and future product candidates; the implementation of our strategic plans for our business, product candidates, research programs and technologies; developments related to our competitors and our industry; our competitive position and the success of competing therapies that are or may become available; our ability to maintain our current license agreements and collaborations and identify and enter into future license agreements and collaborations; the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators in the future; our reliance on third parties for manufacturing and to conduct preclinical studies and clinical trials of our product candidates; our ability to efficiently and cost-effectively conduct our current and future clinical trials; the costs of operating as a public company; the accuracy of our estimates regarding future expenses, future revenue, capital requirements and the need for additional financing; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and other factors specified under the heading "Risk Factors" in Atrium's Registration Statement on Form 10-12B/A, as amended (File No. 001-43008), which was filed with the SEC and became effective on February 26, 2026, most recent Quarterly Report on Form 10-Q filed with the SEC and in other filings and furnishings made by Atrium with the SEC from time to time, which are all available on the SEC's website at www.sec.gov. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.
Atrium Therapeutics, Inc. Selected Condensed Financial Information (in thousands except share and per share information) (Unaudited) | ||||||||
Statements of Operations | ||||||||
Three Months Ended March 31, | ||||||||
2026 | 2025 | |||||||
Collaboration revenue | $ | 19,635 | $ | 1,573 | ||||
Operating expenses: | ||||||||
Research and development | 16,657 | 6,937 | ||||||
General and administrative | 20,258 | 2,088 | ||||||
Total operating expenses | 36,915 | 9,025 | ||||||
Loss from operations | (17,280) | (7,452) | ||||||
Other income, net | 647 | 3 | ||||||
Net loss and comprehensive loss | $ | (16,633) | $ | (7,449) | ||||
Basic and diluted net loss per common share | $ | (0.97) | $ | (0.44) | ||||
Weighted average common shares outstanding used in the calculation of basic and diluted | 17,105,643 | 17,105,643 | ||||||
Balance Sheets | ||||||||
March 31, | December 31, | |||||||
2026 | 2025 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 267,849 | $ | — | ||||
Collaboration receivable | 15,000 | — | ||||||
Prepaid assets | 2,578 | 1,535 | ||||||
Other current assets | 138 | 1,310 | ||||||
Total current assets | 285,565 | 2,845 | ||||||
Restricted cash | 415 | — | ||||||
Property and equipment, net | 4,337 | 2,724 | ||||||
Right-of-use asset | 2,043 | 2,784 | ||||||
Total assets | $ | 292,360 | $ | 8,353 | ||||
Liabilities and Stockholders' Equity/Former Parent Deficit | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 807 | $ | 4,398 | ||||
Accrued liabilities | 6,983 | 8,945 | ||||||
Accrued compensation | 2,091 | 3,147 | ||||||
Lease liabilities | 2,680 | 3,672 | ||||||
Deferred revenue, current portion | 9,344 | 21,639 | ||||||
Total current liabilities | 21,905 | 41,801 | ||||||
Deferred revenue, net of current portion | 36,351 | 28,691 | ||||||
Other long-term liabilities | — | 574 | ||||||
Total liabilities | 58,256 | 71,066 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity/ Former Parent's deficit: | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 16 | — | ||||||
Additional paid-in capital | 221,960 | — | ||||||
Retained earnings | 12,128 | — | ||||||
Net Investment from Former Parent | — | (62,713) | ||||||
Total stockholders' equity/Former Parent's deficit | 234,104 | (62,713) | ||||||
Total liabilities and Stockholders' equity/Former Parent's deficit | $ | 292,360 | $ | 8,353 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-reports-first-quarter-2026-financial-results-302772898.html
SOURCE Atrium Therapeutics